loader
Please Wait
Applying Filters...

Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about Livoletide, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    Livoletide

    DEVELOPMENTS

    PharmaCompass

    Inke S.A: APIs manufacturing plant.

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    2D Structure
    1. Also known as: Azp-531, Azp 531, 9vhd7j6363, 3-((3s,6s,9s,12s,15s,18s,21s,24s)-6,15-bis(3-amino-3-oxo-propyl)-12-(3-guanidinopropyl)-3-(hydroxymethyl)-18-(1h-imidazol-5-ylmethyl)-9-isopropyl-2,5,8,11,14,17,20,23-octaoxo-1,4,7,10,13,16,19,22-octazabicyclo(22.3.0)heptacosan-21-yl)propanoic acid, Livoletide [inn], Unii-9vhd7j6363
    Molecular Formula
    C40H63N15O13
    Molecular Weight
    962.0  g/mol
    InChI Key
    JXPWLIYXIWGWSA-CLBRJLNISA-N
    FDA UNII
    9VHD7J6363
    Livoletide is under investigation in clinical trial NCT03790865 (Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome).
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    3-[(3S,6S,9S,12S,15S,18S,21S,24S)-6,15-bis(3-amino-3-oxopropyl)-12-[3-(diaminomethylideneamino)propyl]-3-(hydroxymethyl)-18-(1H-imidazol-5-ylmethyl)-2,5,8,11,14,17,20,23-octaoxo-9-propan-2-yl-1,4,7,10,13,16,19,22-octazabicyclo[22.3.0]heptacosan-21-yl]propanoic acid
    2.1.2 InChI
    InChI=1S/C40H63N15O13/c1-19(2)31-38(67)51-23(8-11-29(42)58)34(63)53-26(17-56)39(68)55-14-4-6-27(55)37(66)50-24(9-12-30(59)60)33(62)52-25(15-20-16-45-18-47-20)36(65)49-22(7-10-28(41)57)32(61)48-21(35(64)54-31)5-3-13-46-40(43)44/h16,18-19,21-27,31,56H,3-15,17H2,1-2H3,(H2,41,57)(H2,42,58)(H,45,47)(H,48,61)(H,49,65)(H,50,66)(H,51,67)(H,52,62)(H,53,63)(H,54,64)(H,59,60)(H4,43,44,46)/t21-,22-,23-,24-,25-,26-,27-,31-/m0/s1
    2.1.3 InChI Key
    JXPWLIYXIWGWSA-CLBRJLNISA-N
    2.1.4 Canonical SMILES
    CC(C)C1C(=O)NC(C(=O)NC(C(=O)N2CCCC2C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCN=C(N)N)CCC(=O)N)CC3=CN=CN3)CCC(=O)O)CO)CCC(=O)N
    2.1.5 Isomeric SMILES
    CC(C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)CCC(=O)N)CC3=CN=CN3)CCC(=O)O)CO)CCC(=O)N
    2.2 Other Identifiers
    2.2.1 UNII
    9VHD7J6363
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Azp531

    2. Cyclci Dag(6-13)

    3. Cyclic Des-acyl Ghrelin (6-13)

    2.3.2 Depositor-Supplied Synonyms

    1. Azp-531

    2. Azp 531

    3. 9vhd7j6363

    4. 3-((3s,6s,9s,12s,15s,18s,21s,24s)-6,15-bis(3-amino-3-oxo-propyl)-12-(3-guanidinopropyl)-3-(hydroxymethyl)-18-(1h-imidazol-5-ylmethyl)-9-isopropyl-2,5,8,11,14,17,20,23-octaoxo-1,4,7,10,13,16,19,22-octazabicyclo(22.3.0)heptacosan-21-yl)propanoic Acid

    5. Livoletide [inn]

    6. Unii-9vhd7j6363

    7. Azp531

    8. Chembl2029605

    9. Gtpl10884

    10. Cyclo(des-acyl Ghrelin(6-13))

    11. Hy-p0231

    12. Cs-7528

    13. Db15188

    14. Q27896244

    15. Synthetic Cyclic 8 Amino Acid Analog Of Human Unacylated Ghrelin

    16. Cyclo(l-arginyl-l-valyl-l-glutaminyl-l-seryl-l-prolyl-l-.alpha.-glutamyl-l-histidyl-l-glutaminyl)

    17. Cyclo(l-arginyl-l-valyl-l-glutaminyl-l-seryl-l-prolyl-l-alpha-glutamyl-l-histidyl-l-glutaminyl)

    2.4 Create Date
    2012-07-09
    3 Chemical and Physical Properties
    Molecular Weight 962.0 g/mol
    Molecular Formula C40H63N15O13
    XLogP3-5.5
    Hydrogen Bond Donor Count14
    Hydrogen Bond Acceptor Count15
    Rotatable Bond Count17
    Exact Mass961.47297712 g/mol
    Monoisotopic Mass961.47297712 g/mol
    Topological Polar Surface Area461 Ų
    Heavy Atom Count68
    Formal Charge0
    Complexity1900
    Isotope Atom Count0
    Defined Atom Stereocenter Count8
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Treatment of Prader-Willi syndrome

    Post Enquiry
    POST ENQUIRY